Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT02140281Phase 1Completed
Phase 1, randomised, open-label trial of tenapanor in irritable bowel syndrome (IBS) and hyperphosphatemia (2 arms), sponsored by Ardelyx. Primary endpoints: Area Under the Concentration-Time Curve at Day 5 and Maximal Plasma Concentration at Day 5. Started May 2014; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT02140281.